Literature DB >> 33899255

Reduced Synaptic Density in Patients with Lewy Body Dementia: An [11 C]UCB-J PET Imaging Study.

Katrine B Andersen1, Allan K Hansen1, Malene F Damholdt2, Jacob Horsager1, Casper Skjaerbaek1, Hanne Gottrup3, Henriette Klit3, Erik H Danielsen3, David J Brooks1,4,5, Per Borghammer1.   

Abstract

BACKGROUND: Patients with Parkinson's disease (PD) often develop dementia, but the underlying substrate is incompletely understood. Generalized synaptic degeneration may contribute to dysfunction and cognitive decline in Lewy body dementias, but in vivo evidence is lacking.
OBJECTIVE: The objective of this study was to assess the density of synapses in non-demented PD (nPD) subjects (N = 21), patients with PD-dementia or Dementia with Lewy bodies (DLB) (N = 13), and age-matched healthy controls (N = 15).
METHOD: Using in vivo PET imaging and the novel synaptic-vesicle-glycoprotein 2A (SV2A) radioligand [11C]UCB-J, SUVR-1 values were obtained for 12 pre-defined regions. Volumes-of-interest were defined on MRI T1 scans. Voxel-level between-group comparisons of [11C]UCB-J SUVR-1 were performed. All subjects underwent neuropsychological assessment. Correlations between [11C]UCB- J PET and domain-specific cognitive functioning were examined.
RESULTS: nPD patients only demonstrated significantly reduced SUVR-1 values in the substantia nigra (SN) compared to HC. DLB/PDD patients demonstrated reduced SUVR-1 values in SN and all cortical VOIs except for the hippocampus and amygdala. The voxel-based analysis supported the VOI results. Significant correlation was seen between middle frontal gyrus [11C]UCB-J SUVR-1 and performance on tests of executive function.
CONCLUSION: Widespread cortical reduction of synaptic density was documented in a cohort of DLB/PDD subjects using in vivo [11C]UCB-J PET. Our study confirms previously reported synaptic loss in SN of nPD patients. [11C]UCB-J binding in selected cortical VOIs of the DLB/PDD patients correlated with their levels of cognitive function across relevant neuropsychological domains. These findings suggest that the loss of synaptic density contributes to cognitive impairment in nPD and DLB/PDD.
© 2021 International Parkinson and Movement Disorder Society. © 2021 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; dementia; [11C]UCB-J PET; synapse; neuropsychology

Year:  2021        PMID: 33899255     DOI: 10.1002/mds.28617

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  6 in total

Review 1.  Fluid markers of synapse degeneration in synucleinopathies.

Authors:  Alba Cervantes González; Olivia Belbin
Journal:  J Neural Transm (Vienna)       Date:  2022-02-11       Impact factor: 3.575

Review 2.  Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes.

Authors:  Oliver D Howes; Connor Cummings; George E Chapman; Ekaterina Shatalina
Journal:  Neuropsychopharmacology       Date:  2022-09-02       Impact factor: 8.294

Review 3.  The role of neuroimaging in Parkinson's disease.

Authors:  Natasha S R Bidesi; Ida Vang Andersen; Albert D Windhorst; Vladimir Shalgunov; Matthias M Herth
Journal:  J Neurochem       Date:  2021-10-03       Impact factor: 5.546

Review 4.  Synaptic Vesicle Glycoprotein 2A: Features and Functions.

Authors:  Rachele Rossi; Shokouh Arjmand; Simone Larsen Bærentzen; Albert Gjedde; Anne M Landau
Journal:  Front Neurosci       Date:  2022-04-28       Impact factor: 5.152

5.  Synaptic Loss in Multiple Sclerosis: A Systematic Review of Human Post-mortem Studies.

Authors:  E E Amelie Möck; Eveliina Honkonen; Laura Airas
Journal:  Front Neurol       Date:  2021-11-29       Impact factor: 4.003

6.  Topologically convergent and divergent morphological gray matter networks in early-stage Parkinson's disease with and without mild cognitive impairment.

Authors:  Xueling Suo; Du Lei; Nannan Li; Junying Li; Jiaxin Peng; Wenbin Li; Jing Yang; Kun Qin; Graham J Kemp; Rong Peng; Qiyong Gong
Journal:  Hum Brain Mapp       Date:  2021-07-28       Impact factor: 5.038

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.